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Summary
Background Cryotherapy is standard practice for treating patients with cervical precancer in see-and-treat programmes 
in low-income and middle-income countries (LMICs). Because of logistical difficulties with cryotherapy (eg, the 
necessity, costs, and supply chain difficulties of refrigerant gas; equipment failure; and treatment duration >10 min), 
a battery-operated thermal ablator that is lightweight and portable has been developed. We aimed to compare thermal 
ablation using the new device with cryotherapy.
Methods We report the pilot phase of a randomised controlled trial in routine screen-and-treat clinics providing 
cervical screening using visual inspection with acetic acid (VIA) in Lusaka, Zambia. We recruited non-pregnant 
women, aged 25 years or older, who were eligible for ablative therapy. We randomly assigned participants (1:1:1) to 
thermal ablation, cryotherapy, or large loop excision of the transformation zone (LLETZ), using computer-generated 
allocation. The randomisation was concealed but the nurses providing treatment and the participants were unmasked. 
Thermal ablation was achieved using the Liger thermal ablator (using 1–5 overlapping applications of the probe 
heated to 100°C, each application lasting for 40 s), cryotherapy was carried out using the double-freeze technique 
(freeze for 3 min, thaw for 5 min, and freeze again for 3 min), and LLETZ (using a large loop driven by an electro-
surgical unit to excise the transformation zone) was done under local anaesthesia. The primary endpoint was 
treatment success, defined as either human papillomavirus (HPV) type-specific clearance among participants who 
were positive for the same HPV type at baseline, or a negative VIA test at 6-month follow-up, if the baseline HPV test 
was negative. Per protocol analyses were done. Enrolment for the full trial is ongoing. Here, we present findings from 
a prespecified pilot phase of the full trial. The final analysis of the full trial will assess non-inferiority of the groups for 
the primary efficacy endpoint. The study is registered with ClinicalTrials.gov, number NCT02956239.
Findings Between Aug 2, 2017, and Jan 15, 2019, 750 participants were randomly assigned (250 per group). 206 (84%) 
participants in the cryotherapy group, 197 (81%) in the thermal ablation group, and 204 (84%) in the LLETZ group 
attended the 6-month follow-up examination. Treatment success was reported in 120 (60%) of 200 participants in the 
cryotherapy group, 123 (64%) of 192 in the thermal ablation group, and 134 (67%) of 199 in the LLETZ group (p=0·31). 
Few participants complained of moderate to severe pain in any group immediately after the procedure (six [2%] of 
250 in the cryotherapy group, four [2%] of 250 in the thermal ablation group, and five [2%] of 250 in the LLETZ group) 
and 2 weeks after the procedure (one [<1%] of 241 in the cryotherapy group, none of 242 in the thermal ablation 
group, and two [<1%] of 237 in the LLETZ group). None of the participants reported any complication requiring 
medical consultation or admission to hospital.
Interpretation Results from this pilot study preliminarily suggest that thermal ablation has similar treatment success 
to cryotherapy, without the practical disadvantages of providing cryotherapy in an LMIC. However, the study was not 
powered to establish the similarity between the techniques, and results from the ongoing randomised controlled trial 
are need to confirm these results.
Funding US National Institutes of Health.
Introduction
Systematic high coverage and quality-assured population 
screening, with treatment of precursors to cervical 
cancer, is highly effective i n p reventing t he d isease, 
which is not surprising given that the conditions for an 
ideal screening test1 apply very precisely to cervical 
cancer. The disease has a long precancerous phase, 
effective easy screening tests are available, treatment of 
precursors is highly effective, and the disease is common 
enough to justify the expense of population screening, 
even in low-income and middle-income countries 
(LMICs).2 Large loop excision of the transformation zone 
(LLETZ),3 also known as loop electrosurgical excision 
procedure (LEEP), has become the standard treatment 
in most high-income countries. Ablative techniques are 
simpler, safer, and less technically demanding than 
LLETZ. Available ablative methods are cryotherapy and 
thermal ablation. The techniques have been described in 
detail elsewhere.4 Thermal ablation was previously 
known as cold coagulation to distinguish it from radical 
diathermy, which reaches temperatures of approximately 
300°C.5 Thermal ablation functions by heating the 
epithelium at the transformation zone, albeit to 100°C.
Screening by visual inspection with acetic acid (VIA),6 
followed by immediate treatment of VIA-positive women 
(screen-and-treat approach) can reduce the number of 
clinic visits by women and greatly improve treatment 
compliance.7 Cryotherapy was previously recommended 
by WHO as the ablative method of choice for screen-
and-treat programmes in LMICs.8 The method has the 
advantage of not requiring electricity, being simple to 
use, and being effective. However, the costs and 
difficulties in ensuring uninterrupted supply of CO2 or 
N2O refrigerant gas, the long treatment duration 
(11 min), and difficulties with equipment failure have led 
to the frustration of treatment providers with the 
method.9,10 Thermal ablation is an alternative ablation 
therapy to cryotherapy. Similar effectiveness between the 
two methods has been shown in a pooled analysis of 
published observational studies.11,12 The method has a 
much faster treatment duration (20–40 s) and requires 
no gas supply. Like cryotherapy, thermal ablation is 
simple to use and could be given by almost any health-
care provider.
Consequently, the search for a simpler, affordable, and 
mobile ablative treatment modality to incorporate into 
see-and-treat regimes in LMICs has led to the 
development of a cordless, lightweight, and battery-
operated thermal ablator. The International Agency for 
Research on Cancer (IARC) and the University of 
North Carolina (NC, USA) collaborated with Liger 
Medical (UT, USA) to assess the new device. Here, 
we report the pilot phase outcomes of a three-group 
randomised controlled trial of thermal ablation using the 
new portable device compared with cryotherapy and 
LLETZ in the context of a VIA-based screen-and-treat 
programme in Lusaka, Zambia. We aimed to compare 
the success of the three treatment methods. We also 
aimed to estimate the proportion of over-treatment in a 
VIA screen-and-treat programme on the basis of the 
histopathology results after LLETZ in the LLETZ group.
Methods
Study design and participants
This prospective, unblinded, randomised trial was done 
in a primary health clinic participating in the routine 
Research in context
Evidence before this study
The see-and-treat approach, by reducing the number of clinic 
visits, improves treatment compliance in a cervical cancer 
screening programme in resource-limited settings. Screening 
cervical cancer by visual inspection with acetic acid (VIA) 
followed by immediate cryotherapy is the most commonly 
used approach in low-income and middle-income countries 
(LMICs).Thermal ablation is an alternative ablative procedure. 
WHO has endorsed cryotherapy as the standard method of 
treatment for patients with cervical pre-cancer in LMICs for 
more than a decade. Although cold coagulation (now known as 
thermal ablation) has been in use for many years in the UK and 
elsewhere, and despite evidence from large and long-term 
follow-up studies in Scotland, the method has not been 
accepted in LMICs, perhaps largely because of the WHO 
endorsement of cryotherapy. We searched PubMed with no 
language or date restrictions using the keywords “cervical 
intraepithelial neoplasia OR CIN OR cervical precancerous 
lesions” and “ablative treatment”, and “LMICs” on Sept 7, 2018, 
for articles describing this ablative procedure in low-resource 
settings. We also checked the reference lists of the selected 
articles. A meta-analysis of the available published evidence 
revealed similar effectiveness of cryotherapy and thermal 
ablation. We found only one small randomised controlled trial 
in the studies included.
Added value of this study
The results of the pilot phase of our study revealed a similarity 
in efficacy between thermal ablation and cryotherapy, although 
the pilot study was not adequately powered because of the 
small sample size. We found no difference in complication or 
discomfort levels between the study groups. The excisional 
group revealed that only 25% of participants who were deemed 
to be screen positive and eligible for ablation had high-grade 
squamous lesions. The study adds valuable evidence for similar 
efficacy and safety of the two ablative techniques. The high rate 
of over-treatment in a screen-and-treat setting has been 
quantified.
Implications of all the available evidence
The study will continue until sufficient power has been 
achieved to establish equivalent efficacy between thermal 
ablation and cryotherapy. The results of this pilot study suggest 
that thermal ablation as a method of treating cervical 
precancers is as safe as cryotherapy and is highly acceptable to 
patients and providers. If the early results of the pilot study 
regarding the similarity of treatment efficacy between thermal 
ablation and cryotherapy are supported by our ongoing 
randomised controlled trial, thermal ablation without the 
practical disadvantages of cryotherapy will be the ablative 
treatment of choice in an LMIC setting.
screen-and-treat programme in Lusaka, Zambia, where 
VIA is done by trained nurses to screen women aged 
between 25 and 49 years. Like many other LMICs, the 
access to quality assured cytology is poor in Lusaka and 
we, therefore, decided to adhere to the national protocol 
of VIA-based screening followed by treatment of screen-
positive women.
Here, we present findings from a prespecified pilot 
phase of the full trial. This pilot phase was done on 
request of the funder, a condition set before further 
funding for the full trial could be awarded.
All women attending the study VIA screening clinic 
were counselled about the trial by a research nurse before 
going to the clinic room. VIA was performed done as 
described by the IARC manual on VIA, 13 and the VIA 
outcomes were categorised as negative, positive, and 
suspected cancer.13 The examining nurses assessed the 
eligibility of VIA-positive women for ablative treatment. 
These eligibility criteria were that the transformation 
zone be a type 1 (completely ectocervical), not involving 
more than 75% of the ectocervix, not extending to the 
vagina, and with no suspicion of cancer.4,14 Women who 
were eligible for ablative treatment by the clinic nurse 
were invited to participate in the trial. Eligible women 
who agreed to take part in the study then gave written, 
informed consent. Exclusion criteria were any reason 
whereby informed consent was not freely given, not 
eligible for ablative treatment, size of the lesion was such 
that it could not be covered by the largest cryotherapy 
probe, pregnancy, previous treatment to the cervix for 
any reason, and any genital tract cancer.
As per routine practice in Zambia, all women 
undergoing VIA underwent HIV testing, unless a test 
result from within the past 6 months was available. 
Recently diagnosed HIV positivity required initiation of 
antiretroviral therapy before cervical cancer screening.
This study was approved by the research ethics 
committee at IARC, the University of North Carolina, the 
University of Zambia, and the National Health Research 
Agency of Zambia. The full trial protocol can be provided 
on request.
Randomisation and masking
Eligible participants were randomly assigned (1:1:1) to 
receive either thermal ablation, cryotherapy, or LLETZ. 
All treatment was given by one of four study nurses at 
the clinic. A request for allocation was obtained by the 
study nurse after checking the inclusion and exclusion 
criteria. Concealed allocation to a study group was done 
using computer-generated sealed envelopes at IARC, 
which were accessed by the study coordinator in the 
clinic. Study group allocation was conveyed to the nurse 
immediately before treating eligible participants. Once a 
treatment group had been allocated, the participant 
received a unique identifier number. Neither the treating 
nurse, nor the participant, were masked to the treatment 
allocation.
Procedures
The nurse collected a cervical sample before VIA 
using a Cervex-brush (Rovers Medical Devices [Oss, 
the Netherlands]) in Preservcyt medium (Hologic 
[Marlborough, MA, USA]) for human papillomavirus 
(HPV) DNA testing. If a woman was randomly 
assigned, her sample was sent to the University 
Teaching Hospital, Lusaka, laboratory for the detection 
of DNA of any of the 14 high-risk HPV types (with type-
specific information) using the Xpert HPV test (Cepheid 
[Sunnyvale, CA, USA]). The HPV genotype information 
was obtained in separate channels for HPV 16; HPV 18 
and 45; HPV 31, 33, 35, 52, and 58; HPV 51 and 59; and 
HPV 39, 56, 66, and 68. The test results were obtained 
after randomisation and treatment and did not alter 
treatment allocation or the management of eligible 
VIA-positive women.
Thermal ablation was done using the Liger thermal 
ablator and as described in the IARC colposcopy manual.15
The portable battery-driven thermal ablator was developed 
by Liger Medical (Lehi, UT, USA) during 2016 and 
2017 and bench tested in 2017. US Food and Drug 
Administration clearance was obtained in 2017, as was 
the European CE mark. The device is powered by a small 
removable 12-volt battery that is incorporated into the 
handle, which can be recharged over 2–3 h and holds 
enough charge to complete at least 20 treatment 
procedures. The thermal ablator probe was heated to 
100°C and applied over the transformation zone of the 
cervix for 40 s. Up to five overlapping applications, each 
lasting for 40 s were used to treat a large transformation 
zone.
Cryotherapy was carried out using the double-freeze 
technique (freeze for 3 min, thaw for 5 min, and freeze 
again for 3 min) as per routine practice in screen-and-
treat programmes in Zambia.4 LLETZ was done 
under local anaesthesia, as described by Prendiville and 
colleagues.3 Briefly, a type 1 excision of the transformation 
zone was done using a large yet shallow metallic loop, 
following local infiltration with 1% lignocaine. No 
anaesthesia was used for either thermal ablation or 
cryotherapy. Any treatment side-effects during and 
immediately after treatment were recorded by the nurse 
providing the treatment. Safety was assessed as any major 
complications leading to hospitalisation, disability, or 
death.
The treating nurse counselled each participant after 
the procedure about possible side-effects and 
complications of treatment and advised participants to 
report to the clinic or call the study coordinator for 
advice. Abstinence from sexual intercourse for 6 weeks 
and avoidance from douching or any vaginal 
medications was advised. Neither analgesics nor 
antibiotics were prescribed. Every participant was 
invited to attend a follow-up clinic appointment at 
6 months. Before leaving the clinic, participants were 
interviewed by the project coordinator to document 
their perception of pain and discomfort during and 
immediately after treatment and also their satisfaction 
with the overall experience. Pain and satisfaction were 
assessed using a visual rating scale ranging from 1 (no 
pain at all or was highly satisfied) to 9 (pain was so 
severe that the participant wanted the procedure to be 
stopped or was not at all satisfied).
The study coordinator phoned each participant 
2 weeks after treatment to check whether she had any 
compli cations, had visited a clinician, or had been 
admitted to hospital during the intervening period. 
The level of pain and discomfort and the degree of 
satisfaction with the overall experience at that timepoint 
was again recorded.
At the 6-month follow-up visit, each participant 
was asked about any complications, medical consul-
tations, or hospitalisations. Participants were examined 
by a study nurse, who first collected a cervical sample 
for Xpert HPV testing and did VIA screening. 
VIA-positive participants were immediately referred 
for further assessment and appropriate management 
as per the local protocol. Participants who were negative 
on VIA, but positive for HPV, were advised to attend a 
repeat follow-up visit at 12 months.
Outcomes
The primary outcome was success of treatment at 
6 months, which was defined as either HPV type-
specific clearance at 6 months among participants 
positive for the same HPV type at baseline, or negative 
VIA test at follow-up, if the baseline HPV test was 
negative. The secondary outcomes were safety and 
acceptability of the three treatment methods. The 
proportion of participants undergoing LLETZ and 
having cervical intraepithelial neoplasias (CIN) on 
histopathology was also assessed as a secondary 
outcome, which helped us to assess the degree of over-
treatment in screen-and-treat settings.
Statistical analysis
The sample size of 250 participants per group that was 
used for the assessment of the preliminary safety and 
efficacy was empirically decided. Recruitment for the 
full trial is ongoing and is expected to complete recruit-
ment and follow-up within 2 years. A data and safety 
monitoring board continues to oversee the project.
The primary outcome was analysed per protocol. 
Treatment success, side-effects, complications, and 
acceptability presented as propor tions and were compared 
between the three treatment modalities using a two-tailed 
Fisher’s exact test. The interval between treatment and 
follow-up was compared using the Kruskal-Wallis equality-
of-popu lations rank test. Statistical significance was set as 
p<0·05. Treated participants who had not yet reported for 
their 6-month follow-up (including those who were not yet 
eligible or those who were eligible, but did not attend a 
follow-up visit) were deemed not assessable in the analysis 
of the primary endpoint in the pilot phase. Statistical 
analyses were done using STATA (version 14.0) and R 
(version 3.6.0).
This study is registered with ClinicalTrials.gov, 
numberNCT02956239.
1890 with lesions ineligible for ablation
250 randomly assigned to cryotherapy
246 eligible for 6-month follow-up
206 attended follow-up
40 had not yet attended follow-up
4 had not reached 6 months after
 treatment at time of analysis
250 randomly assigned to thermal ablation
244 eligible for 6-month follow-up
197 attended follow-up
47 had not yet attended follow-up
6 had not reached 6 months after
 treatment at time of analysis
250 randomly assigned to LLETZ
245 eligible for 6-month follow-up
204 attended follow-up
41 had not yet attended follow-up
5 had not reached 6 months after
 treatment at time of analysis
750 suitable for ablative treatment and randomly
assigned
297 not suitable for ablative treatment and referred 
for further management outside of study
1047 VIA positive and assessed for suitability
for ablative treatment
2937 patients screened for eligibility
Figure: Trial profile
VIA=visual inspection with acetic acid. LLETZ=large loop excision of the transformation zone.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The raw data was accessed by RM (study 
statistician), PB, EL, and WP. The corresponding author 
had full access to all of the data and the final responsibility 
to submit for publication.
Results
Between Aug 2, 2017 and Jan 15, 2019, we assessed 
2937 participants for eligibility (figure). We stopped 
recruitment for the pilot phase after 750 eligible 
participants were recruited. Participants were randomly 
assigned to thermal ablation (n=250), cryotherapy 
(n=250), or LLETZ (n=250). Table 1 provides details of the 
baseline sociodemographic, reproductive, and clinical 
characteristics between the three treatment groups.
In the cryotherapy group, 246 (98%) participants 
completed 6 months of treatment and were eligible for 
6-month follow-up, of whom 206 (84%) attended the
6-month follow-up examination. In the thermal ablation
group, 244 (98%) participants were eligible for 6-month
follow-up and 197 (81%) attended the 6-month follow-up
examination, and in the LLETZ group, 245 (98%) were
eligible for 6-month follow-up and 204 (84%) attended








25–29 92 (37%) 89 (356%) 84 (34%)
30–34 54 (22%) 65 (26%) 64 (26%)
35–39 44 (18%) 37 (15%) 47 (19%)
40–44 35 (14%) 31 (12%) 37 (15%)
45–49 15 (6%) 17 (7%) 11 (4%)
50–54 9 (4%) 8 (3%) 6 (2%)
55–60 1 (<1%) 3 (1%) 1 (<1%)
Education
None 9 (4%) 7 (3%) 10 (4%)
Primary 88 (35%) 75 (30%) 74 (30%)
Secondary 101 (40%) 128 (51%) 123 (49%)
College or 
university
50 (20%) 40 (16%) 41 (16%)
Unknown 2 (<1%) 0 2 (<1%)
Occupation
Housewife 62 (25%) 68 (27%) 57 (23%)
Manual 26 (10%) 23 (9%) 29 (12%)
Professional 43 (17%) 44 (18%) 37 (15%)
Business 92 (37%) 81 (32%) 86 (34%)
Other 16 (6%) 29 (12%) 31 (12%)
Unknown 11 (4%) 5 (2%) 10 (4%)
Marital status
Unmarried 34 (14%) 32 (13%) 35 (14%)
Married or 
cohabiting
168 (67%) 171 (68%) 157 (63%)
Widowed 19 (8%) 17 (7%) 24 (10%)
Separated 28 (11%) 30 (12%) 34 (14%)
Unknown 1 (<1%) 0 0
Residence area
Urban 146 (58%) 152 (61%) 149 (60%)
Semiurban 92 (37%) 90 (36%) 94 (38%)
Rural 11 (4%) 7 (3%) 7 (3%)
Unknown 1 (<1%) 1 (<1%) 0
Total pregnancies
None 21 (8%) 14 (6%) 20 (8%)
1–2 74 (30%) 88 (35%) 102 (41%)
3–4 93 (37%) 90 (36%) 79 (32%)
≥5 62 (25%) 58 (23%) 49 (20%)







(Continued from previous column)
Total livebirths
None 28 (11%) 22 (9%) 29 (12%)
1–2 97 (39%) 109 (44%) 120 (48%)
3–4 87 (35%) 85 (34%) 71 (28%)
≥5 38 (15%) 34 (14%) 30 (12%)
Last menstruation
≤30 days 217 (87%) 213 (85%) 215 (86%)
>30 days to 
<12 months
18 (7%) 21 (8%) 22 (9%)
≥12 months 2 (<1%) 6 (2%) 3 (1%)
Unknown 13 (5%) 10 (4%) 10 (4%)
Size of the acetowhite area
<50% of TZ 221 (88%) 223 (89%) 210 (84%)
>50% of TZ 29 (12%) 27 (11%) 40 (16%)
Baseline HIV status
Negative 108 (43%) 119 (48%) 110 (44%)
Positive 134 (54%) 123 (49%) 135 (54%)
Unknown 8 (3%) 8 (3%) 5 (2%)
HIV positive on ART
Yes 129/134 (96%) 117/123 (95%) 130/135 (96%)
No 4/134 (3%) 5/123 (4%) 1/135 (<1%)
Unknown 1/134 (<1%) 1/123 (<1%) 4/135 (3%)
HPV testing results
Negative 100 (40%) 113 (45%) 105 (42%)
Positive 150 (60%) 136 (55%) 145 (58%)
Unknown 0 1 (<1%) 0
HPV type*
HPV 16 38 (15%) 41 (17%) 51 (20%)
HPV 18 or 45 24 (10%) 21 (8%) 21 (8%)
HPV 31, 33, 35, 
52, 58
99 (40%) 94 (38%) 101 (40%)
HPV 51 or 59 20 (8%) 11 (4%) 12 (5%)
HPV 39, 56, 66, 
or 68
60 (24%) 45 (18%) 54 (22%)
Data are n (%) or n/N (%). LLETZ=large loop excision of the transformation zone. 
ART=antiretroviral therapy. HPV=human papillomavirus. *Some patients had 
combinations of multiple HPV genotypes.
Table 1: Baseline characteristics
interval between treatment and follow-up was 6·0 months 
(IQR 6·0–6·4 months) and the mean was 6·6 months 
(SD 1·8 months; range 4·8–19·6 months), with no 
difference between the treatment groups (p=0·83).
Table 2 shows treatment success proportions at 
6 months after treatment based on a combination of 
HPV test and VIA. HPV reports were missing in six 
participants in the cryotherapy group, five participants 
in the thermal ablation group, and five participants in 
the LLETZ group, and these individuals were excluded 
from the analysis. When based on HPV type-specific 
clearance and VIA-negative findings among participants 
who were HPV negative at baseline, the proportions of 
participants treated successfully were 120 (60%) of 
200 in the cryotherapy group, 123 (64%) of 192 in 
the thermal ablation group, and 134 (67%) of 
199 in the LLETZ group (p=0·52). The proportions 
of participants with clearance of high-risk HPV at 
6 months were similar between the cryotherapy 
(48 [40%] of 121), thermal ablation (44 [42%] of 104), and 
LLETZ (50 [47%] of 106) groups (p=0·48). The proportion 
of participants with clearance of HPV 16 (14 [43%] of 
32 in the cryotherapy group, 18 [64%] of 28 in the 
thermal ablation group, and 18 [55%] of 33 in the LLETZ 
group) was lower than the proportion of participants 
clearing HPV 18, HPV 45, or both (16 [100%] of 16 in the 
cryotherapy group, 11 [69%] of 16 in the thermal ablation 
group, and 14 [88%] of 16 in the LLETZ group). 
Participants who were HIV-positive had lower treatment 
success than those who were HIV negative, irrespective 
of the treatment method (table 2). The proportions of 
successful treatment as reflected by VIA examination 
alone were similar across the groups (data not shown). 
The proportions of participants who had a normal VIA 
examination at follow-up were 162 (79%) of 204 in the 
cryotherapy group, 162 (84%) of 193 in the thermal 
ablation group, and 162 (80%) of 203 in the LLETZ 
group (p=0·47).
Almost all participants reported no or the least level of 
discomfort with their treatment, either immediately 
after or within 2 weeks of treatment, across all 
three groups (table 3). Few complained of moderate-to-
severe pain immediately after the procedure and we 
found no statistically significant difference between the 
groups (table 3). When asked about the level of 
satisfaction with the service provided at the clinic and 
whether or not they would recommend the treatment to 
a friend, almost all women (99–100%) in each of the 
three groups reported that they would, both immediately 
and at 2 weeks after treatment. Five deaths occured 
(three in the cryotherapy group and one each in the 
thermal ablation and LLETZ groups, due to intimate 
partner violence, suicide, metastatic breast cancer, renal 
failure of unknown cause, and complications following a 
excision of a soft tissue tumour on the thigh); none of 
the deaths were related to treatment. None of the 
participants reported any complications requiring 
medical consultation or hospitalisation.
73 (31%) of 238 participants who underwent LLETZ 
and had histological evidence of CIN 2–3 (table 4). More 
than half of the VIA-positive participants (124 [52%] of 
238) had some grade of CIN and none had invasive
cancer. VIA-positive women aged 30–39 years had a
higher proportion of CIN 2 or worse, compared with
those aged 25–29 years and with those aged 40 years and
older (table 4). In HIV-positive participants who were
eligible for ablation, 55 (43%) of 128 had CIN 2–3,
compared with 17 (16%) of 106 participants who were
HIV negative. Of the HPV-positive (and VIA-positive)
participants who had LLETZ, 64 (46%) of 138 had
histologically proven CIN 2–3, compared with only
nine (9%) of 100 who were HPV negative. Taking baseline 
combinations of high-risk HPV and HIV status, CIN 2–3
was detected in three (5%) of 66 participants who were
negative for HPV and HIV, six (19%) of 32 participants
who were HPV negative and HIV positive, 14 (35%) of
40 participants who were HPV positive and HIV negative, 
and 49 (51%) of 96 participants who were positive for
HPV and HIV.
Discussion
To our knowledge, this study is the only report from a 
randomised study that assessed acceptability, safety, and 
performance of thermal ablation using a modern battery-
driven portable machine. The most important finding of 
the preliminary report of our study is that thermal 
ablation appears to be acceptable to women and is 





LLETZ group Fisher’s exact 
p value
Overall
Participants followed up* 200 192 199 ··
Participants with no evidence of 
disease
120 (60%) 123 (64%) 134 (67%) 0·52
HPV positive at baseline
High-risk participants followed up 121 104 106 ··
Participants with no evidence of 
disease
48 (40%) 44 (42%) 50 (47%) 0·48
HIV negative at baseline
Participants followed up 85 93 93 ··
Participants with no evidence of 
disease
68 (80%) 77 (83%) 76 (82%) 0·72
HIV positive at baseline
Participants followed up 109 95 101 ··
Participants with no evidence of 
disease
50 (46%) 42 (44%) 55 (54·5) 0·36
Data are n, or n (%). LLETZ=large loop excision of the transformation zone. HPV=human papillomavirus. VIA=visual 
inspection with acetic acid. Treatment success was defined as either HPV type-specific clearance at 6 months among 
women positive for the same HPV type at baseline, or negative VIA test at follow-up, if the baseline HPV test was 
negative. *HPV reports were missing in six participants in the cryotherapy group, five participants in the thermal 
ablation group, and five participants in the LLETZ group, who had HPV-positive results at baseline; these participants 
were excluded from the analysis of treatment success proportion.
Table 2: Treatment success proportions at 6-months follow-up after treatment
trial suggest similar performance between thermal 
ablation and cryotherapy in terms of treatment success; 
however, this pilot study was not powered for this 
outcome.
The shorter treatment time, less cumbersome 
equipment, and non-dependance on refrigerant gas are 
distinct advantages of thermal ablation over cryotherapy. 
The cost of the battery driven thermal ablation is similar 
to that of standard cryotherapy equipment and a huge 
cost saving is expected because of low operational 
costs, if cryotherapy is replaced by thermal ablation. 
Moreover, current battery-operated thermal ablators are 
small, lightweight, and highly portable. Avoiding 
cumbersome gas tanks is a practical advantage to health-
care providers in LMICs.
Our results are particularly informative because of the 
high proportion of HIV-positive women in the study 
partici pants. The results suggest that thermal ablation 
using the Liger thermal ablator is safe in HIV-positive 
women. The preliminary results also suggest similar 
performance for the two ablative techniques in HIV-
positive women, albeit substantially lower than that in 
HIV-negative women. Because the trial was implemented 
in routine health-care facilities in Zambia and treatment 
was provided by regular in-service nursing staff, the 
results could be generalisable to other LMIC settings.
Thermal ablation has been used extensively in Scotland 
since Semm first introduced the technique in Germany 
in the 1960s, and more recently in many other parts of the 
world. In Scotland, Duncan16 has produced the largest 
and longest series of patients treated with thermal 
ablation (1453 patients followed up for >14 years) and the 
proportions of treatment success in his case series 
compare favourably with other treatment methods.17 
The effectiveness of thermal ablation has been assessed 
in several meta-analyses.11,12 Randall and colleagues12 
report an overall treatment success from 16 included 
studies for CIN2 or worse lesions of 93·6% (95% CI 
90·8–96·0). Treatment success was 92·9% (90·4–95·1) 
for CIN1 or worse and was 89·0% (84·0–95·0) for CIN 3. 
The only randomised controlled trial included in the 
analysis was done in Singapore.18 In that study, the 
authors reported no difference i n t reatment s uccess 
between cryotherapy and thermal ablation for any grades 
of CIN. The reported proportions of treatment success 
after thermal ablation in the Singapore study were 88·4% 
for CIN1, 84·2% for CIN2, and 78·6% for CIN3. Duan 
and colleagues19 have also presented the results of a 
randomised controlled trial of thermal ablation versus 
cryotherapy in a study of 149 women eligible for ablative 
therapy. In this study, thermal ablation was equallyor 
more effective t han c ryotherapy w as a t 8  m onths, a s 
judged by HPV and cytological assessment.
There are several limitations in our study. The numbers 
of participants reported are small and the efficacy 
estimates should be interpreted with caution. The study 
continues to recruit eligible women and will do so until 
a sufficient sample size has been reached for the full 
trial. According to our sample size calculation, an 
additional 1000 participants need to be recruited in each 
group to give sufficient power to detect non-inferiority of 
thermal ablation as a treatment method for VIA-positive 
women compared with cryotherapy or LLETZ. A second 
caveat is that follow-up assessment at 6 months is 
probably too early to assess treatment success, but we do 
not anticipate any difference arising between the study 
groups, which are well balanced because of random-
isation. Another limitation of the study is the absence of 
histopathology verification either at baseline or at follow-
up. Ablative techniques are likely to be used widely in 
screen-and-treat settings and we have followed the 
standard of care (ie, VIA) to detect abnormalities before 
or after treatment. VIA is not a perfect screening test, 





LLETZ group Fisher’s exact 
p value
Immediately after treatment
Participants assessed 250 250 250 ··
Intensity of pain or discomfort felt
1 (no pain) 120 (48%) 115 (46%) 134 (54%) 0·40
2–3 (least pain) 123 (49%) 129 (52%) 111 (44%) ··
4–6 6 (2%) 3 (1%) 5 (2%) ··
7–9 (worst pain) 0 1 (<1%) 0 ··
Unknown 1 (<1%) 2 (1%) 0 ··
Level of satisfaction with the services
1–3 (least satisfied) 0 0 0 0·27
4–6 3 (1%) 1 (<1%) 0 ··
7–9 (highly satisfied) 246 (98%) 248 (99%) 250 (100%) ··
Unknown 1 (<1%) 1 (<1%) 0 ··
Will recommend the screening procedure to others
Yes 248 (99%) 250 (100%) 249 (100%) 0·34
No 0 0 1 (<1%) ··
Cannot say 2 (<1%) 0 0 ··
2 weeks after treatment
Participants assessed 241 242 237 ··
Intensity of pain or discomfort felt
1 (no pain) 214 (89%) 227 (94%) 208 (88%) 0·21
2–3 (least pain) 25 (10%) 15 (6%) 27 (11%) ··
4–6 1 (<1%) 0 2 (<1%) ··
7–9 (worst pain) 0 0 0 ··
Level of satisfaction with the services
1–3 (least satisfied) 0 0 0 0·55
4–6 1 (<1%) 0 0 ··
7–9 (highly satisfied) 239 (99%) 242 (100%) 237 (100%) ··
Unknown 1 (<1%) 0 0 ··
Will recommend the screening procedure to others
Yes 239 (99%) 242 (100%) 237 (100%) 0·34
No 0 0 0 ··
Cannot say 2 (<1%) 0 0 ··
Data are n, or n (%). LLETZ=large loop excision of the transformation zone.
Table 3: Intensity of pain and level of satisfaction reported immediately and 2 weeks after treatment
However, WHO recommend VIA for LMICs that cannot 
afford an HPV detection test for population screening. 
The National Cancer Control Strategic Plan (2016–21) by 
the Zambian Ministry of Health also stipulates the use 
of VIA as the screening test of choice, followed by 
immediate cryotherapy or thermal ablation in all VIA-
positive women eligible for ablation.20 We implemented 
a pragmatic study and followed the existing protocol for 
VIA screen and treat. In the VIA screen-and-treat 
programme, a negative VIA result alone is considered as 
the test of cure. To increase the validity of our study, in 
addition to VIA, we used the most frequently used and 
powerful test of cure, which is a validated high-risk HPV 
test. This approach allowed us to investigate the 
association between HPV and VIA status and also to 
have a more valid endpoint than VIA alone. The results 
of HPV testing were masked because of management 
decisions. The low proportions of treatment success, as 
defined by HPV status, might reflect the early follow-up 
at 6 months and the possibility of recurrent infection, 
especially considering the high prevalence of HIV in 
participants. The follow-up VIA might have missed 
some of the lesions in HPV-negative participants 
because of the low sensitivity of the test. However, 
similar success proportions observed between the 
ablative and excisional treatment groups using the 
stringent criteria of disease clearance gives us confidence 
in the findings.
The duration of treatment with thermal ablation is still 
an unresolved issue. Randall and colleagues’12 meta-
analysis found that the proportion of patients achieving a 
cure did not vary significantly according to the duration 
of treatment. The proportions who were successfully 
treated were 92·9% in patients who were treated for 20 s, 
95·1% in those treated for 30 s, and 84·8% in those 
treated for 45 s. In Duncan’s16 case series, 20 s applications 
were used but with the important caveat that where the 
probe tip did not cover the entire transformation zone, 
overlapping applications were made.16 The variables of 
probe tip size and the number of applications are, as yet, 
open questions. So far, in our study we used a duration of 
40 s and multiple overlapping applications using a 
20 mm probe. Our data and safety monitoring board has 
recommended that we reduce the treatment time to 30 s 
in the larger randomised controlled trial because the 
board members could not find evidence in the published 
literature for an advantage of a treatment duration of 
longer than 30 s.
Reassuringly, very low frequencies of discomfort during 
and after treatment were reported in all three study 
groups. The frequencies reported in the procedure room 
during and immediately after treatment were slightly 
lower in the thermal ablation group, which might be 
explained by the shorter treatment duration associated 
with thermal ablation when compared with cryotherapy 
(45 s vs 11 min). The low reporting of pain or cramps 
during LLETZ might be because local infiltration was 
routinely used for LLETZ but not for ablative treatment of 
either kind. Furthermore, similarly low discomfort was 
reported by participants after they had left the procedure 
room and by telephone 2 weeks after treatment.
All participants were advised to avoid penetrative sex 
for 6 weeks to reduce the risk of post-treatment bleeding 
and infection. Although an important concern for HIV-
infected women, viral shedding does not increase after 
ablative treatment if women are already on antiretroviral 
Participants with 
histology report
Histological diagnosis at baseline
Normal CIN1 CIN2 CIN3 CIN2–3
Overall 238/250 (95%) 114/238 (48%) 51/238 (21%) 32/238 (13%) 41/238 (17%) 73/238 (31%)
Age, years
25–29 81/84 (96%) 46/81 (57%) 20/81 (25%) 7/81 (9%) 8/81 (10%) 15/81 (19%)
30–39 105/111 (95%) 42/105 (40%) 18/105 (17%) 21/105 (20%) 24/105 (23%) 45/105 (43%)
≥40 52/55 (95%) 26/52 (50%) 13/52 (25%) 4/52 (8%) 9/52 (17%) 13/52 (25%)
HPV test results
Negative 100/105 (95%) 66/100 (66%) 25/100 (25%) 5/100 (5%) 4/100 (4%) 9/100 (9%)
Positive 138/145 (95%) 48/138 (35%) 26/138 (19%) 27/138 (20%) 37/138 (27%) 64/138 (46%)
Baseline HIV status
Negative 106/110 (96%) 60/106 (57%) 29/106 (27%) 7/106 (7%) 10/106 (9%) 17/106 (16%)
Positive 128/135 (95%) 51/128 (40%) 22/128 (17%) 25/128 (20%) 30/128 (23%) 55/128 (43%)
Baseline HPV and HIV status combinations
HPV negative, HIV negative 66/70 (94%) 44/66 (67%) 19/66 (29%) 2/66 (3%) 1/66 (2%) 3/66 (5%)
HPV negative, HIV positive 32/33 (97%) 20/32 (63%) 6/32 (19%) 3/32 (9%) 3/32 (9%) 6/32 (19%)
HPV positive, HIV negative 40/40 (100%) 16/40 (40%) 10/40 (25%) 5/40 (13%) 9/40 (23%) 14/40 (35%)
HPV positive, HIV positive 96/102 (94%) 31/96 (32%) 16/96 (17%) 22/96 (23%) 27/96 (28%) 49/96 (51%)
Data are n/N (%). LLETZ=large loop excision of the transformation zone. CIN=cervical intraepithelial neoplasia. HPV=human papillomavirus.
Table 4: Histology findings at baseline in the LLETZ group
therapy.21,22 All of our HIV-positive participants were on 
antiretroviral therapy at the time of VIA screening. 
Earlier studies have shown that 5–31% of women treated 
with cryotherapy did not comply with the advice for 
abstinence and the proportion of compliance increases 
with improved counseling.23 Although we ensured 
appropriate counseling of each participant, some parti-
cpants might have been non-compliant and therefore 
had bleeding or infection. However, we found that 
documenting the compliance proportion was difficult 
because of the cultural sensitivities around questions 
related to sexual practices.
One of the reasons that we included a third study group 
(excision by LLETZ) was to investgiate the histological 
diagnosis in VIA-positive women who were eligible for 
cryotherapy and thereby to better assess the test 
characteristics of visual inspection in its ability to 
discriminate between high-grade and low-grade or 
normal transformation zones. Thus, this approach 
allowed the analysis of the proportion of over-treatment 
specifically in the context of a screen-and-treat approach. 
Participants required a type 1 LLETZ, which has been 
shown to be safe in our study. Only 31% of women with a 
positive VIA and who were eligible for an ablative therapy 
had histologically proven high-grade CIN2 or worse. This 
positive predictive value (PPV) is higher for women in 
aged 30–39 years (43%) and for those who are HIV 
positive (43%). Much lower proportions (around 5%) 
have been reported from studies that were done in 
regions with a low prevalence of cervical cancer.24 A meta-
analysis of 26 cross-sectional studies by Sauvaget and 
colleagues observed that the average PPV of VIA to detect 
CIN2 or worse disease was 10%.6 The PPV in our study 
population was higher because of the high prevalence of 
HIV infection. Most of the earlier studies used punch 
biopsy as the gold standard to define disease status. Our 
study provides a more valid estimate of PPV by including 
the entire transformation zone in histopathological 
assessment. Nevertheless, the low PPV and resulting 
over-treatment (nearly half of the women treated had no 
CIN) in a VIA screen-and-treat programme is concerning. 
This finding also underscores the need for a safe 
treatment method that causes minimal discomfort to 
patients. We were reassured to know that no invasive 
cancer was inadvertently treated at least in the LLETZ 
group.
WHO has recently updated its clinical guidelines for 
the treatment of cervical precancer25 and now endorses 
the use of thermal ablation for ablative treatment. The 
low incidence of complications for either intervention 
reported by our study, especially in many HIV-positive 
women, formed part of the evidence for WHO to develop 
the new guidelines. A randomised controlled trial to 
compare thermal ablation with cryotherapy (using 
standard cryotherapy or cryopen) to treat histo patho-
logically proved CIN2 or CIN3 is ongoing in Colombia, 
El Salvadore, and Peru (NCT03084081). If our early 
findings on the similar performance of the two ablative 
techniques are supported by our ongoing large trial and 
other studies, then health-care workers caring for 
screen-positive women in screen-and-treat programmes 
in LMICs could choose modern thermal ablation devices 
that are cordless, lightweight, and battery operated over 
cryotherapy instruments because of the practical 
disadvantages of cryotherapy. In view of the low 
incidence of histologically proven CIN2 or worse in VIA-
screen positive women, the optimal screening test for 
LMICs should perhaps be reconsidered. We hope that 
less expensive HPV tests that do not require elaborate 
laboratory facilities will become available soon or 
alternative techniques—eg, artificial intelligence image 
recognition systems—will emerge.
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